<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02959177</url>
  </required_header>
  <id_info>
    <org_study_id>15796</org_study_id>
    <secondary_id>I5Q-JE-CGAN</secondary_id>
    <nct_id>NCT02959177</nct_id>
  </id_info>
  <brief_title>A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 (Galcanezumab) in Japanese Patients With Episodic Migraine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the efficacy of the study drug Galcanezumab in
      Japanese participants with episodic migraine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2016</start_date>
  <completion_date type="Actual">January 18, 2019</completion_date>
  <primary_completion_date type="Actual">January 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia; The overall mean is derived from the average of months 1 to 6 from mixed model repeat measures (MMRM) model. Least Square Mean (LSMEAN) was calculated using MMRM models with fixed categorical effects of treatment, month, and treatment-by-month interaction, as well as the continuous, fixed covariates of baseline value and baseline-by-month interaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 50% or Greater Reduction From Baseline in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 50% responder in a particular month is any participant who has a ≥50% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 75% or Greater Reduction From Baseline in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 75% responder in a particular month is any participant who has a ≥75% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 100% Reduction From Baseline in Monthly Migraine Headache Days</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 100% responder in a particular month is any participant who has a 100% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline on the Migraine-Specific Quality (MSQ) of Life Questionnaire</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>MSQ version 2.1 is a health status instrument consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement. The overall mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline by month and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in Number of Migraine Headache Days With Acute Medication Use</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Migraine Headache Day (MHD) with Acute Medication Use: Calendar days on which migraine or probable migraine occurs, requiring acute medication.
The overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score</measure>
    <time_frame>Baseline, Month 4 through Month 6</time_frame>
    <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. Least square mean (LSM) was calculated using an MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Mean Change From Baseline in Headache Hours</measure>
    <time_frame>Baseline, Month 1 through Month 6</time_frame>
    <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using the MMRM model with treatment, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</measure>
    <time_frame>Baseline, Month 6</time_frame>
    <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</measure>
    <time_frame>Month 6</time_frame>
    <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Month 1 through Month 6</time_frame>
    <description>C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thoughts occurred. Some questions are binary responses (yes/no) and some are on a scale of 1 (low severity) to 5 (high severity). Suicidal ideation (SI): a &quot;yes&quot; answer to any of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)</measure>
    <time_frame>Month 1 through Month 6</time_frame>
    <description>C -SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab</measure>
    <time_frame>Baseline through Month 6</time_frame>
    <description>Treatment emergent ADA will be defined as any of the following:
A negative baseline result and a positive post-baseline ADA result with a titer ≥20. This is also called treatment-induced ADA.
A positive baseline result and a positive post-baseline ADA result with a ≥4-fold increase in titers (for example, baseline titer of 10 increasing to ≥40 post-baseline). This is called treatment-boosted ADA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</measure>
    <time_frame>Month 6</time_frame>
    <description>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</measure>
    <time_frame>Month 6</time_frame>
    <description>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">459</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>120 milligrams (mg) Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg galcanezumab (LY2951742) administered subcutaneously (SC) once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 mg Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>120 mg galcanezumab (LY2951742) administered SC once a month for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC once a month for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>120 milligrams (mg) Galcanezumab</arm_group_label>
    <arm_group_label>240 mg Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a diagnosis of migraine as defined by International Headache Society (IHS)
             International Classification of Headache Disorders (ICHD)-3 beta guidelines (1.1 or
             1.2) (ICHD-3 2013), with a history of migraine headaches of at least 1 year prior to
             screening, and migraine onset prior to age 50.

        Exclusion Criteria:

          -  Are currently enrolled in or have participated within the last 30 days or within 5
             half-lives (whichever is longer) in a clinical trial involving an investigational
             product.

          -  Current use or prior exposure to Galcanezumab or other antibodies to CGRP or its
             receptor.

          -  Known hypersensitivity to multiple drugs, monoclonal antibodies or other therapeutic
             proteins, or to Galcanezumab and the excipients in the investigational product.

          -  History of persistent daily headache, cluster headache or migraine subtypes including
             hemiplegic (sporadic or familial) migraine, ophthalmoplegic migraine, and migraine
             with brainstem aura (basilar-type migraine) defined by IHS ICHD-3 beta.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chiba</city>
        <zip>275-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Chofu-shi</city>
        <zip>182-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukui</city>
        <zip>918 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukui</city>
        <zip>9188503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Fukuoka</city>
        <zip>816 0824</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Higashioka</city>
        <zip>578-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Hiroshima</city>
        <zip>730-0031</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Iruma-Gun</city>
        <zip>350-0495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kagoshima</city>
        <zip>892-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kasaoka-shi</city>
        <zip>714-0043</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kawasaki</city>
        <zip>211-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kawasaki</city>
        <zip>2118588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kobe</city>
        <zip>658-0064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Kobe</city>
        <zip>6580064</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kochi</city>
        <zip>780-8011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Kyoto</city>
        <zip>606-0851</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Kōchi</city>
        <zip>780-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.&quot;</name>
      <address>
        <city>Matsuyama</city>
        <zip>790-0925</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Matsuyama</city>
        <zip>790-0925</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Minato-Ku</city>
        <zip>108-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Minatoku</city>
        <zip>1088642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morioka</city>
        <zip>020-0034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Morioka</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Morioka</city>
        <zip>0200034</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Niigata</city>
        <zip>9493193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.&quot;</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.</name>
      <address>
        <city>Nishinomiya</city>
        <zip>663-8204</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Oita</city>
        <zip>870-0831</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Okayama-shi</city>
        <zip>700-8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Osaka-Shi</city>
        <zip>556-0015</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Ota-shi</city>
        <zip>373-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saijo-shi</city>
        <zip>793-0030</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Saitama</city>
        <zip>338 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sapporo</city>
        <zip>003-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sapporo</city>
        <zip>060-8570</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Sendai</city>
        <zip>982-0014</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shibuya-ku</city>
        <zip>151-0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>160-0017</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Shizuoka</city>
        <zip>420-0853</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tachikawa-shi</city>
        <zip>190-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tokyo</city>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Tōyama</city>
        <zip>9300803</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamaguchi</city>
        <zip>754-0002</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamanashi</city>
        <zip>400-0124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Yamanashi</city>
        <zip>4000124</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>November 7, 2016</study_first_submitted>
  <study_first_submitted_qc>November 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 8, 2016</study_first_posted>
  <results_first_submitted>January 17, 2020</results_first_submitted>
  <results_first_submitted_qc>February 17, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2020</results_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 15, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02959177/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 30, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/77/NCT02959177/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were randomized to a Treatment Phase with double-blind treatment arms and then could enter a Follow-up Post Treatment Phase.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>120 mg Galcanezumab</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous (SC)injection.</description>
        </group>
        <group group_id="P2">
          <title>240 mg Galcanezumab</title>
          <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo administered SC once a month for 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-Blind Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
                <participants group_id="P2" count="114"/>
                <participants group_id="P3" count="230"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="111"/>
                <participants group_id="P3" count="225"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Post Treatment Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="52">Not all participants entered Post Treatment Follow-up Phase</participants>
                <participants group_id="P2" count="52">Not all participants entered Post Treatment Follow-up Phase</participants>
                <participants group_id="P3" count="100">Not all participants entered Post Treatment Follow-up Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="98"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>120 mg Galcanezumab</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
        </group>
        <group group_id="B2">
          <title>240 mg Galcanezumab</title>
          <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants were administered placebo SC once a month for 6 months..</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="115"/>
            <count group_id="B2" value="114"/>
            <count group_id="B3" value="230"/>
            <count group_id="B4" value="459"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Less than 20 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Greater than 20 years old</title>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="229"/>
                    <measurement group_id="B4" value="457"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="196"/>
                    <measurement group_id="B4" value="387"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Migraine Headache Days (MHD) per month</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.</description>
          <units>days per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.6" spread="2.8"/>
                    <measurement group_id="B2" value="9.0" spread="3.0"/>
                    <measurement group_id="B3" value="8.6" spread="3.0"/>
                    <measurement group_id="B4" value="8.8" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)</title>
        <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia; The overall mean is derived from the average of months 1 to 6 from mixed model repeat measures (MMRM) model. Least Square Mean (LSMEAN) was calculated using MMRM models with fixed categorical effects of treatment, month, and treatment-by-month interaction, as well as the continuous, fixed covariates of baseline value and baseline-by-month interaction.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)</title>
          <description>Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity; AND B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia; The overall mean is derived from the average of months 1 to 6 from mixed model repeat measures (MMRM) model. Least Square Mean (LSMEAN) was calculated using MMRM models with fixed categorical effects of treatment, month, and treatment-by-month interaction, as well as the continuous, fixed covariates of baseline value and baseline-by-month interaction.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>Days</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.60" lower_limit="-4.25" upper_limit="-2.96"/>
                    <measurement group_id="O2" value="-3.36" lower_limit="-4.01" upper_limit="-2.71"/>
                    <measurement group_id="O3" value="-0.59" lower_limit="-1.05" upper_limit="-0.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>-2.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.53</ci_lower_limit>
            <ci_upper_limit>-1.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 50% or Greater Reduction From Baseline in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 50% responder in a particular month is any participant who has a ≥50% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 50% or Greater Reduction From Baseline in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 50% responder in a particular month is any participant who has a ≥50% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.8" spread="3.4"/>
                    <measurement group_id="O2" value="48.2" spread="3.5"/>
                    <measurement group_id="O3" value="20.3" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.71</ci_lower_limit>
            <ci_upper_limit>5.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.664</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.54</ci_lower_limit>
            <ci_upper_limit>5.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 75% or Greater Reduction From Baseline in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 75% responder in a particular month is any participant who has a ≥75% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 75% or Greater Reduction From Baseline in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 75% responder in a particular month is any participant who has a ≥75% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.5" spread="2.8"/>
                    <measurement group_id="O2" value="25.0" spread="2.8"/>
                    <measurement group_id="O3" value="9.6" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.14</ci_lower_limit>
            <ci_upper_limit>4.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.08</ci_lower_limit>
            <ci_upper_limit>4.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 100% Reduction From Baseline in Monthly Migraine Headache Days</title>
        <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 100% responder in a particular month is any participant who has a 100% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 100% Reduction From Baseline in Monthly Migraine Headache Days</title>
          <description>Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred. A 100% responder in a particular month is any participant who has a 100% reduction from baseline in the monthly number of migraine headache attacks in a 30-day interval. It is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>percentage of participants</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" spread="1.5"/>
                    <measurement group_id="O2" value="8.1" spread="1.5"/>
                    <measurement group_id="O3" value="2.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.47</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.03</ci_lower_limit>
            <ci_upper_limit>5.93</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline on the Migraine-Specific Quality (MSQ) of Life Questionnaire</title>
        <description>MSQ version 2.1 is a health status instrument consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement. The overall mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline by month and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline on the Migraine-Specific Quality (MSQ) of Life Questionnaire</title>
          <description>MSQ version 2.1 is a health status instrument consists of 14 items addressing 3 domains:(1)Role Function-Restrictive (items 1-7);(2)Role Function- Preventive (items 8-11);&amp;(3)Emotional Function (items 12-14).Response options range from &quot;none of the time&quot; (value 1) to &quot;all of the time&quot; (value 6), &amp; are reverse-recoded (value 6 to 1) before the domain scores are calculated. Total raw scores for each domain is the sum of the final item value for all of the items in that domain. After total raw score is computed for each domain &amp; total score, they are transformed to a 0-100 scale with higher scores indicating a better health status &amp; a positive change in scores reflecting functional improvement. The overall mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline by month and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.13" lower_limit="15.10" upper_limit="19.15"/>
                    <measurement group_id="O2" value="15.91" lower_limit="13.89" upper_limit="17.93"/>
                    <measurement group_id="O3" value="10.12" lower_limit="8.70" upper_limit="11.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean difference</param_type>
            <param_value>7.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.54</ci_lower_limit>
            <ci_upper_limit>9.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>5.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.33</ci_lower_limit>
            <ci_upper_limit>8.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in Number of Migraine Headache Days With Acute Medication Use</title>
        <description>Migraine Headache Day (MHD) with Acute Medication Use: Calendar days on which migraine or probable migraine occurs, requiring acute medication.
The overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in Number of Migraine Headache Days With Acute Medication Use</title>
          <description>Migraine Headache Day (MHD) with Acute Medication Use: Calendar days on which migraine or probable migraine occurs, requiring acute medication.
The overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>MDHs with medication use</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.02" lower_limit="-3.60" upper_limit="-2.43"/>
                    <measurement group_id="O2" value="-2.81" lower_limit="-3.40" upper_limit="-2.23"/>
                    <measurement group_id="O3" value="-0.12" lower_limit="-0.53" upper_limit="0.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean difference</param_type>
            <param_value>-2.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.61</ci_lower_limit>
            <ci_upper_limit>-2.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean difference</param_type>
            <param_value>-2.70</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.41</ci_lower_limit>
            <ci_upper_limit>-1.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score</title>
        <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. Least square mean (LSM) was calculated using an MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
        <time_frame>Baseline, Month 4 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in the Patient Global Impression of Severity (PGI-S) Score</title>
          <description>The PGI-S scale is a patient-rated instrument that measures patients own global impression of their illness severity. The patient was instructed as follows: &quot;Considering migraine as a chronic condition, how would you rate your level of illness?&quot; Response options were from 1 (&quot;normal, not at all ill&quot;) to 7 (&quot;extremely ill&quot;). Mean is derived from the average of months 4 to 6 from MMRM model. Least square mean (LSM) was calculated using an MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
                <count group_id="O3" value="228"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-0.40" upper_limit="-0.10"/>
                    <measurement group_id="O2" value="-0.41" lower_limit="-0.56" upper_limit="-0.25"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.26" upper_limit="-0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Mean Change From Baseline in Headache Hours</title>
        <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using the MMRM model with treatment, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
        <time_frame>Baseline, Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Mean Change From Baseline in Headache Hours</title>
          <description>Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using the MMRM model with treatment, month, treatment by month, baseline, baseline by month and baseline MHD category.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>hours per month</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.56" lower_limit="-18.10" upper_limit="-11.01"/>
                    <measurement group_id="O2" value="-16.46" lower_limit="-20.02" upper_limit="-12.90"/>
                    <measurement group_id="O3" value="-2.73" lower_limit="-5.25" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-11.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.14</ci_lower_limit>
            <ci_upper_limit>-7.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean difference</param_type>
            <param_value>-13.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.05</ci_lower_limit>
            <ci_upper_limit>-9.40</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
        <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
        <time_frame>Baseline, Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline on the Migraine Disability Assessment Test (MIDAS) Total Score</title>
          <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability.
LSMean was calculated using MMRM model with treatment, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.</description>
          <population>All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="114"/>
                <count group_id="O2" value="113"/>
                <count group_id="O3" value="229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" lower_limit="-9.67" upper_limit="-4.44"/>
                    <measurement group_id="O2" value="-5.13" lower_limit="-7.69" upper_limit="-2.58"/>
                    <measurement group_id="O3" value="-2.16" lower_limit="-3.96" upper_limit="-0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-4.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.06</ci_lower_limit>
            <ci_upper_limit>-1.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>LSMean Difference</param_type>
            <param_value>-2.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.08</ci_lower_limit>
            <ci_upper_limit>0.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</title>
        <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had Month 6 PSMQ-M measurement.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Positive Responses on Patient Satisfaction With Medication Questionnaire-Modified (PSMQ-M)</title>
          <description>The PSMQ-M is a self-rated scale which measures participants level of satisfaction with study medication.The scale has been modified for use in this study, assessing 3 items related to the clinical trial treatment over the past 4 weeks: satisfaction, preference, and side effects. Satisfaction responses range from &quot;very unsatisfied&quot; to &quot;very satisfied&quot; with the current treatment. Preference compares the current study medication to previous medications, with responses from &quot;much rather prefer my previous medication&quot; to &quot;much rather prefer the medication administered to me during the study&quot;</description>
          <population>All randomized participants who received at least one dose of study drug and had Month 6 PSMQ-M measurement.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="111"/>
                <count group_id="O3" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Satisfaction: Very satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.58"/>
                    <measurement group_id="O2" value="44.14"/>
                    <measurement group_id="O3" value="7.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Satisfaction: Somewhat satisfied</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.92"/>
                    <measurement group_id="O2" value="23.42"/>
                    <measurement group_id="O3" value="27.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side effects: Much less side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.58"/>
                    <measurement group_id="O2" value="28.83"/>
                    <measurement group_id="O3" value="24.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side effects: Less side effects</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.12"/>
                    <measurement group_id="O2" value="33.33"/>
                    <measurement group_id="O3" value="25.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preference: Prefer study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.38"/>
                    <measurement group_id="O2" value="34.23"/>
                    <measurement group_id="O3" value="28.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Preference: Much Prefer study medication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.12"/>
                    <measurement group_id="O2" value="27.03"/>
                    <measurement group_id="O3" value="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
        <description>C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thoughts occurred. Some questions are binary responses (yes/no) and some are on a scale of 1 (low severity) to 5 (high severity). Suicidal ideation (SI): a &quot;yes&quot; answer to any of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent</description>
        <time_frame>Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had at least one post baseline C-SSRS assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Ideations Collected by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
          <description>C-SSRS captures the occurrence, severity, and frequency of suicide-related thoughts during the assessment period. The scale includes suggested questions to solicit the type of information needed to determine if a suicide-related thoughts occurred. Some questions are binary responses (yes/no) and some are on a scale of 1 (low severity) to 5 (high severity). Suicidal ideation (SI): a &quot;yes&quot; answer to any of 5 suicidal ideation questions: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods without intent to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent</description>
          <population>All randomized participants who received at least one dose of study drug and had at least one post baseline C-SSRS assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Wish to be dead</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-specific active suicidal thoughts</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI with no intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI with some intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Active SI with specific plan and intent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
        <description>C -SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
        <time_frame>Month 1 through Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection..</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Suicidal Behaviors Assessed by Columbia - Suicide Severity Rating Scale (C-SSRS)</title>
          <description>C -SSRS captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior is defined as a &quot;yes&quot; answer to any of 5 suicidal behavior questions: preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide. Suicidal ideation is defined as a &quot;yes&quot; answer to any one of 5 suicidal ideation questions: wish to be dead, and 4 different categories of active suicidal ideation.</description>
          <population>All randomized participants who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Preparatory acts or behavior</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aborted attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-fatal suicide attempt</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Completed suicide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab</title>
        <description>Treatment emergent ADA will be defined as any of the following:
A negative baseline result and a positive post-baseline ADA result with a titer ≥20. This is also called treatment-induced ADA.
A positive baseline result and a positive post-baseline ADA result with a ≥4-fold increase in titers (for example, baseline titer of 10 increasing to ≥40 post-baseline). This is called treatment-boosted ADA.</description>
        <time_frame>Baseline through Month 6</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug and had evaluable immunogenicity data.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Developing Anti-Drug Antibodies (ADA) to Galcanezumab</title>
          <description>Treatment emergent ADA will be defined as any of the following:
A negative baseline result and a positive post-baseline ADA result with a titer ≥20. This is also called treatment-induced ADA.
A positive baseline result and a positive post-baseline ADA result with a ≥4-fold increase in titers (for example, baseline titer of 10 increasing to ≥40 post-baseline). This is called treatment-boosted ADA.</description>
          <population>All randomized participants who received at least 1 dose of study drug and had evaluable immunogenicity data.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="115"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="230"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.57"/>
                    <measurement group_id="O2" value="10.53"/>
                    <measurement group_id="O3" value="1.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</title>
        <description>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</title>
          <description>Pharmacokinetics (PK): Serum Concentration of Galcanezumab</description>
          <population>All randomized participants who received at least one dose of study drug and had measurable serum concentrations.</population>
          <units>nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20400" spread="7490"/>
                    <measurement group_id="O2" value="40600" spread="18400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
        <description>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
        <time_frame>Month 6</time_frame>
        <population>All randomized participants who received at least one dose of study drug and had measurable CGRP concentrations.</population>
        <group_list>
          <group group_id="O1">
            <title>120 mg Galcanezumab</title>
            <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
          </group>
          <group group_id="O2">
            <title>240 mg Galcanezumab</title>
            <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants were administered placebo SC once a month for 6 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</title>
          <description>Total Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)</description>
          <population>All randomized participants who received at least one dose of study drug and had measurable CGRP concentrations.</population>
          <units>nanograms per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="104"/>
                <count group_id="O2" value="110"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.35" spread="1.25"/>
                    <measurement group_id="O2" value="5.40" spread="1.53"/>
                    <measurement group_id="O3" value="0.634" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 months</time_frame>
      <desc>All randomized participants who received at least 1 dose of study drug during treatment phase and remained in follow-up phase.
Gender specific events only occurring in male or female participants have had the number of participants At Risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Phase Placebo</title>
          <description>Participants were administered placebo SC once a month for 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Treatment Phase 120 mg Galcanezumab</title>
          <description>Participants received loading dose of 240mg (2 injections of 120mg each) galcanezumab at first doing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.</description>
        </group>
        <group group_id="E3">
          <title>Treatment Phase 240 mg Galcanezumab</title>
          <description>Participants received 240 mg galcanezumab administered SC once a month for 6 months.</description>
        </group>
        <group group_id="E4">
          <title>Follow-up Phase Placebo</title>
          <description>Participants did not receive study drug</description>
        </group>
        <group group_id="E5">
          <title>Follow-up 120 mg Galcanezumab</title>
          <description>Participants did not receive study drug</description>
        </group>
        <group group_id="E6">
          <title>Follow-up Phase 240 mg Galcanezumab</title>
          <description>Participants did not receive study drug</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 21.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="230"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="115"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="114"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="100"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="52"/>
                <counts group_id="E6" subjects_affected="20" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Eustachian tube patulous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eustachian tube stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meniere's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Autoimmune thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Corneal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Foreign body sensation in eyes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ocular hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Abdominal wall haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Allergic stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cheilitis granulomatosa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Colitis ischaemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="230"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis eosinophilic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oroantral fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hangover</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site discolouration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="46" subjects_affected="17" subjects_at_risk="115"/>
                <counts group_id="E3" events="84" subjects_affected="31" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" events="14" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="24" subjects_affected="10" subjects_at_risk="115"/>
                <counts group_id="E3" events="59" subjects_affected="23" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="22" subjects_affected="12" subjects_at_risk="115"/>
                <counts group_id="E3" events="22" subjects_affected="12" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Papillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Puncture site induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Bacterial vulvovaginitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="230"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="115"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="103" subjects_affected="76" subjects_at_risk="230"/>
                <counts group_id="E2" events="43" subjects_affected="31" subjects_at_risk="115"/>
                <counts group_id="E3" events="34" subjects_affected="28" subjects_at_risk="114"/>
                <counts group_id="E4" events="5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oesophageal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="115"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Chillblains</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dental restoration failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fractured coccyx</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Heat illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cardiac function test abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>White blood cells urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nodal osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Kidney angiomyolipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Facial spasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Migraine without aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Occipital neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Radial nerve palsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="96"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Premenstrual syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pruritus genital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="196"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Withdrawal bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="196"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="96"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="5" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Asteatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Solar dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Menopause</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="84"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="43"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Endodontic procedure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Maxillary antrum operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Skin cyst excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Wisdom teeth removal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="230"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="230"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="115"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
      <email>Clinicaltrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

